Amicus Therapeutics Company Profile (NASDAQ:FOLD)

About Amicus Therapeutics (NASDAQ:FOLD)

Amicus Therapeutics logoAmicus Therapeutics, Inc. is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. Its pipeline also includes SD-101, which is a product candidate in late-stage development, as a potential first-to-market therapy for the chronic, rare connective tissue disorder Epidermolysis Bullosa (EB). It is also leveraging its Chaperone-Advanced Replacement Therapy (CHART) platform technologies to develop ERT products for Pompe disease, Fabry disease, and potentially other lysosomal storage disorders (LSDs). The Company is also investigating preclinical and discovery programs in other rare and devastating diseases, including cyclin-dependent kinase-like 5 (CDKL5) deficiency.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:FOLD
  • CUSIP: 03152W10
  • Web:
  • Market Cap: $1.13 billion
  • Outstanding Shares: 142,916,000
Average Prices:
  • 50 Day Moving Avg: $7.45
  • 200 Day Moving Avg: $6.74
  • 52 Week Range: $4.41 - $9.61
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.55
  • P/E Growth: -0.16
Sales & Book Value:
  • Annual Revenue: $9.13 million
  • Price / Sales: 124.13
  • Book Value: $2.18 per share
  • Price / Book: 3.64
  • EBIDTA: ($179,310,000.00)
  • Return on Equity: -55.51%
  • Return on Assets: -20.56%
  • Current Ratio: 2.59%
  • Quick Ratio: 2.55%
  • Average Volume: 2.79 million shs.
  • Beta: 1.55
  • Short Ratio: 10.04

Frequently Asked Questions for Amicus Therapeutics (NASDAQ:FOLD)

What is Amicus Therapeutics' stock symbol?

Amicus Therapeutics trades on the NASDAQ under the ticker symbol "FOLD."

How were Amicus Therapeutics' earnings last quarter?

Amicus Therapeutics, Inc. (NASDAQ:FOLD) posted its quarterly earnings data on Tuesday, May, 9th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.37) by $0.02. The business had revenue of $4.20 million for the quarter, compared to analysts' expectations of $4.16 million. The business's revenue was up 50.0% compared to the same quarter last year. View Amicus Therapeutics' Earnings History.

Where is Amicus Therapeutics' stock going? Where will Amicus Therapeutics' stock price be in 2017?

6 brokers have issued 1 year price targets for Amicus Therapeutics' stock. Their forecasts range from $9.00 to $16.00. On average, they anticipate Amicus Therapeutics' share price to reach $12.50 in the next year. View Analyst Ratings for Amicus Therapeutics.

What are analysts saying about Amicus Therapeutics stock?

Here are some recent quotes from research analysts about Amicus Therapeutics stock:

  • 1. According to Zacks Investment Research, "AMICUS THERAPEUTICS is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal(TM) for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for the treatment of Gaucher disease. " (5/12/2017)
  • 2. Cowen and Company analysts commented, "FOLD announced interim Pompe Ph1/2 ATB200/AT2221 PK/PD data from the first 4." (12/8/2016)

Are investors shorting Amicus Therapeutics?

Amicus Therapeutics saw a increase in short interest in the month of May. As of May 15th, there was short interest totalling 36,448,651 shares, an increase of 1.4% from the April 28th total of 36,967,851 shares. Based on an average daily volume of 2,356,514 shares, the days-to-cover ratio is presently 15.5 days. Currently, 26.6% of the shares of the company are sold short.

Who are some of Amicus Therapeutics' key competitors?

Who owns Amicus Therapeutics stock?

Amicus Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include FMR LLC (14.52%), Perceptive Advisors LLC (12.11%), Redmile Group LLC (7.96%), Jennison Associates LLC (6.33%), Vanguard Group Inc. (6.09%) and Palo Alto Investors LLC (5.52%). Company insiders that own Amicus Therapeutics stock include Bradley L Campbell, Daphne Quimi, Dipal Doshi, Donald J Hayden Jr, Ellen Rosenberg, Enrique Dilone, Glenn Sblendorio, Hung Do, Jay Barth, Jayne Gershkowitz, Jeff Castelli, John F Crowley, Julie Yu, Ken Valenzano, Kenneth Peist, Margaret G Mcglynn, Perceptive Advisors Llc and William D Baird III. View Institutional Ownership Trends for Amicus Therapeutics.

Who sold Amicus Therapeutics stock? Who is selling Amicus Therapeutics stock?

Amicus Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Redmile Group LLC, FMR LLC, Jennison Associates LLC, Sphera Funds Management LTD., UBS Group AG, Candriam Luxembourg S.C.A. and Bank of America Corp DE. Company insiders that have sold Amicus Therapeutics stock in the last year include Bradley L Campbell, Daphne Quimi, Hung Do, Jay Barth, Perceptive Advisors Llc and William D Baird III. View Insider Buying and Selling for Amicus Therapeutics.

Who bought Amicus Therapeutics stock? Who is buying Amicus Therapeutics stock?

Amicus Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Morgan Stanley, Point72 Asset Management L.P., Palo Alto Investors LLC, Canada Pension Plan Investment Board, Victory Capital Management Inc., Vanguard Group Inc. and Janus Capital Management LLC. Company insiders that have bought Amicus Therapeutics stock in the last two years include Ellen Rosenberg, Margaret G Mcglynn and Perceptive Advisors Llc. View Insider Buying and Selling for Amicus Therapeutics.

How do I buy Amicus Therapeutics stock?

Shares of Amicus Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Amicus Therapeutics stock cost?

One share of Amicus Therapeutics stock can currently be purchased for approximately $7.93.

Analyst Ratings

Consensus Ratings for Amicus Therapeutics (NASDAQ:FOLD) (?)
Ratings Breakdown: 6 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $12.50 (57.63% upside)

Analysts' Ratings History for Amicus Therapeutics (NASDAQ:FOLD)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/25/2017Bank of America CorpLower Price TargetBuy$10.00 -> $9.00MediumView Rating Details
5/17/2017Robert W. BairdReiterated RatingOutperform$10.00 -> $12.00HighView Rating Details
3/30/2017Leerink SwannReiterated RatingOutperform$15.00MediumView Rating Details
12/8/2016Cowen and CompanySet Price TargetBuy$12.00N/AView Rating Details
11/30/2016JPMorgan Chase & Co.Reiterated RatingOverweight$12.00 -> $11.00N/AView Rating Details
11/29/2016Chardan CapitalReiterated RatingBuy$15.00 -> $16.00N/AView Rating Details
3/30/2016Goldman Sachs Group IncInitiated CoverageNeutral$10.00N/AView Rating Details
3/8/2016Janney Montgomery ScottUpgradeNeutral -> Buy$10.00 -> $12.00N/AView Rating Details
6/16/2015B. RileyBoost Price TargetBuy$14.00 -> $17.50N/AView Rating Details
(Data available from 5/27/2015 forward)


Earnings History for Amicus Therapeutics (NASDAQ:FOLD)
Earnings by Quarter for Amicus Therapeutics (NASDAQ:FOLD)
Earnings History by Quarter for Amicus Therapeutics (NASDAQ:FOLD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017($0.37)($0.39)$4.16 million$4.20 millionViewListenView Earnings Details
3/1/2017Q4 2016($0.33)($0.32)$3.16 million$2.83 millionViewListenView Earnings Details
11/7/2016Q3($0.31)($0.33)$1.71 million$2.10 millionViewListenView Earnings Details
8/9/2016Q2($0.33)($0.40)$0.17 millionViewN/AView Earnings Details
5/3/2016Q1($0.34)($0.35)ViewListenView Earnings Details
11/3/2015Q3($0.25)($0.32)ViewN/AView Earnings Details
8/5/2015Q215($0.24)($0.26)ViewN/AView Earnings Details
5/5/2015Q115($0.14)($0.25)$0.50 millionViewN/AView Earnings Details
3/3/2015Q414($0.18)($0.24)$0.48 millionViewN/AView Earnings Details
11/6/2014Q3 2014($0.21)($0.22)$1.00 million$0.29 millionViewN/AView Earnings Details
8/7/2014Q2 2014($0.24)($0.23)$0.48 millionViewN/AView Earnings Details
5/5/2014Q1 2014($0.23)($0.25)$0.20 million$0.46 millionViewN/AView Earnings Details
3/3/2014Q4 13($0.32)($0.22)$0.32 millionViewN/AView Earnings Details
11/11/2013Q3($0.32)($0.29)ViewN/AView Earnings Details
8/7/2013Q2 2013($0.35)($0.31)ViewN/AView Earnings Details
5/9/2013Q1 2013($0.30)($0.34)ViewN/AView Earnings Details
11/5/2012Q312($0.24)($0.31)$8.82 million$5.80 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Amicus Therapeutics (NASDAQ:FOLD)
2017 EPS Consensus Estimate: ($1.45)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.39)($0.39)($0.39)
Q2 20171($0.35)($0.35)($0.35)
Q3 20171($0.36)($0.36)($0.36)
Q4 20171($0.35)($0.35)($0.35)
(Data provided by Zacks Investment Research)


Dividend History for Amicus Therapeutics (NASDAQ:FOLD)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Amicus Therapeutics (NASDAQ:FOLD)
Insider Ownership Percentage: 3.40%
Insider Trades by Quarter for Amicus Therapeutics (NASDAQ:FOLD)
Institutional Ownership by Quarter for Amicus Therapeutics (NASDAQ:FOLD)
Insider Trades by Quarter for Amicus Therapeutics (NASDAQ:FOLD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/19/2017Hung DoInsiderSell29,914$8.00$239,312.00View SEC Filing  
3/2/2017Bradley L CampbellCOOSell49,050$8.00$392,400.00View SEC Filing  
1/13/2017Hung DoInsiderSell25,000$6.00$150,000.00View SEC Filing  
12/30/2016Perceptive Advisors LlcMajor ShareholderBuy94,750$4.96$469,960.00View SEC Filing  
12/29/2016Perceptive Advisors LlcMajor ShareholderBuy142,125$4.87$692,148.75View SEC Filing  
12/23/2016Perceptive Advisors LlcMajor ShareholderBuy85,275$4.81$410,172.75View SEC Filing  
12/22/2016Perceptive Advisors LlcMajor ShareholderBuy189,500$4.51$854,645.00View SEC Filing  
11/9/2016Daphne QuimiSVPSell8,546$8.00$68,368.00View SEC Filing  
11/1/2016Hung DoInsiderSell25,000$7.00$175,000.00View SEC Filing  
10/3/2016Hung DoInsiderSell25,000$7.25$181,250.00View SEC Filing  
9/20/2016William D Baird IIICFOSell20,500$8.00$164,000.00View SEC Filing  
9/6/2016Hung DoInsiderSell25,000$7.00$175,000.00View SEC Filing  
8/25/2016Perceptive Advisors LlcInsiderSell1,100,000$6.81$7,491,000.00View SEC Filing  
8/4/2016Jay BarthInsiderSell10,458$7.00$73,206.00View SEC Filing  
7/27/2016Jay BarthInsiderSell20,916$7.00$146,412.00View SEC Filing  
6/2/2016Ellen RosenbergGeneral CounselBuy15,000$7.67$115,050.00View SEC Filing  
11/10/2015Margaret G McglynnDirectorBuy10,000$10.27$102,700.00View SEC Filing  
10/7/2015Perceptive Advisors LlcMajor ShareholderBuy50,000$6.27$313,500.00View SEC Filing  
10/6/2015Perceptive Advisors LlcMajor ShareholderBuy750,000$6.71$5,032,500.00View SEC Filing  
10/1/2015Kenneth PeistVPSell10,000$13.14$131,400.00View SEC Filing  
9/21/2015Bradley L. CampbellCOOSell13,001$16.78$218,156.78View SEC Filing  
9/21/2015William D. Baird IIICFOSell15,236$16.78$255,660.08View SEC Filing  
9/15/2015Hung DoInsiderSell25,000$17.75$443,750.00View SEC Filing  
9/14/2015Daphne QuimiVPSell2,500$18.08$45,200.00View SEC Filing  
7/16/2015John F CrowleyCEOSell16,025$16.00$256,400.00View SEC Filing  
7/14/2015John F CrowleyCEOSell142,250$15.03$2,138,017.50View SEC Filing  
7/13/2015Glenn SblendorioDirectorSell10,000$15.00$150,000.00View SEC Filing  
7/13/2015John F CrowleyCEOSell7,750$15.01$116,327.50View SEC Filing  
7/13/2015Ken ValenzanoSVPSell15,000$15.00$225,000.00View SEC Filing  
7/8/2015Dipal DoshiSVPSell6,250$13.87$86,687.50View SEC Filing  
7/1/2015Jayne GershkowitzSVPSell10,649$13.97$148,766.53View SEC Filing  
7/1/2015Kenneth PeistVPSell10,000$13.98$139,800.00View SEC Filing  
6/23/2015Donald J Hayden JrDirectorSell55,000$14.01$770,550.00View SEC Filing  
6/22/2015Jeff CastelliSVPSell18,981$13.94$264,595.14View SEC Filing  
6/19/2015Bradley L CampbellCOOSell13,000$13.26$172,380.00View SEC Filing  
6/19/2015Enrique DiloneSVPSell14,045$13.26$186,236.70View SEC Filing  
6/19/2015William D Baird IIICFOSell15,235$13.26$202,016.10View SEC Filing  
6/15/2015Jeff CastelliSVPSell7,377$14.17$104,532.09View SEC Filing  
6/15/2015Julie YuVPSell8,195$14.17$116,123.15View SEC Filing  
6/8/2015Jeff CastelliSVPSell17,312$12.87$222,805.44View SEC Filing  
6/8/2015John F CrowleyCEOSell55,000$13.01$715,550.00View SEC Filing  
5/11/2015Jeff CastelliSVPSell10,000$10.84$108,400.00View SEC Filing  
5/11/2015Kenneth PeistVPSell12,500$10.84$135,500.00View SEC Filing  
5/11/2015William D Baird IIICFOSell24,800$10.84$268,832.00View SEC Filing  
4/15/2015Glenn SblendorioDirectorSell20,000$12.50$250,000.00View SEC Filing  
4/15/2015Ken ValenzanoVPSell5,000$12.50$62,500.00View SEC Filing  
4/10/2015John F CrowleyCEOSell11,678$12.00$140,136.00View SEC Filing  
4/1/2015Jeff CastelliVPSell9,489$10.69$101,437.41View SEC Filing  
1/5/2015Jeff CastelliVPSell4,667$9.00$42,003.00View SEC Filing  
12/4/2014John F CrowleyCEOSell89,000$8.36$744,040.00View SEC Filing  
11/25/2014Bradley L CampbellCOOSell7,250$8.00$58,000.00View SEC Filing  
11/25/2014Jeff CastelliVPSell8,103$8.00$64,824.00View SEC Filing  
11/25/2014William D Baird IIICFOSell10,000$8.00$80,000.00View SEC Filing  
11/19/2014Perceptive Advisors LlcMajor ShareholderBuy2,100,000$6.50$13,650,000.00View SEC Filing  
10/27/2014Plc GlaxosmithklineMajor ShareholderSell11,315,825$5.29$59,860,714.25View SEC Filing  
10/3/2014Jeff CastelliVPSell8,552$7.00$59,864.00View SEC Filing  
10/3/2014William D Baird IIICFOSell10,000$7.00$70,000.00View SEC Filing  
10/2/2014Julie YuVPSell4,759$5.99$28,506.41View SEC Filing  
9/29/2014Daphne QuimiVPSell10,738$6.10$65,501.80View SEC Filing  
9/29/2014William D Baird IIICFOSell25,311$6.09$154,143.99View SEC Filing  
8/27/2014Glenn SblendorioDirectorSell10,000$6.50$65,000.00View SEC Filing  
8/27/2014Jayne GershkowitzVPSell5,000$7.00$35,000.00View SEC Filing  
8/25/2014Bradley L CampbellCOOSell7,000$6.00$42,000.00View SEC Filing  
8/25/2014Jayne GershkowitzVPSell5,000$6.00$30,000.00View SEC Filing  
8/20/2014Bradley L CampbellCOOSell18,750$5.40$101,250.00View SEC Filing  
8/20/2014Enrique DiloneVPSell12,810$5.40$69,174.00View SEC Filing  
6/30/2014Perceptive Advisors LlcMajor ShareholderBuy4,000,000$3.50$14,000,000.00View SEC Filing  
11/20/2013Plc Glaxosmithklinemajor shareholderBuy1,500,000$2.00$3,000,000.00View SEC Filing  
3/15/2013Sol J BarerDirectorBuy25,000$3.40$85,000.00View SEC Filing  
11/13/2012Joan WinterbottomSVPBuy1,665$4.54$7,559.10View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Amicus Therapeutics (NASDAQ:FOLD)
Latest Headlines for Amicus Therapeutics (NASDAQ:FOLD)
DateHeadline logoBank of America Corp Lowers Amicus Therapeutics, Inc. (FOLD) Price Target to $9.00 - May 27 at 1:24 PM logo$6.96 Million in Sales Expected for Amicus Therapeutics, Inc. (FOLD) This Quarter - May 27 at 9:02 AM logoAmicus Therapeutics, Inc. (FOLD) Expected to Post Earnings of -$0.37 Per Share - May 25 at 8:04 AM logoAmicus Therapeutics: A Rare Find In Biotechnology - Seeking Alpha - May 24 at 10:05 PM logoAmicus Therapeutics, Inc. (FOLD) Insider Sells $239,312.00 in Stock - May 23 at 8:19 PM logoAmicus Therapeutics (FOLD) Presents At UBS Global Healthcare Conference 2017 - Slideshow - May 23 at 4:55 PM logoAmicus Therapeutics, Inc. (FOLD) Given Average Rating of "Buy" by Brokerages - May 23 at 7:32 AM logoForm 8-K AMICUS THERAPEUTICS INC For: May 19 - - May 19 at 10:02 PM logoAmicus Therapeutics Announces Planned Analysis of Primary Endpoints in Phase 3 Epidermolysis Bullosa Study - May 19 at 5:01 PM logoToday's Research Reports on Biotech Stocks to Watch: Exelixis and Amicus Therapeutics - May 18 at 10:06 AM logoAmicus Therapeutics, Inc. (FOLD) Stock Rating Reaffirmed by Robert W. Baird - May 17 at 11:02 PM logoFY2018 EPS Estimates for Amicus Therapeutics, Inc. Reduced by Leerink Swann (FOLD) - May 17 at 12:50 PM logoAmicus Therapeutics (FOLD) Announces Positive Data from Pompe Phase 1/2 Study - May 15 at 4:54 PM logoAmicus Therapeutics Announces Positive Functional Data from Initial Patients in Pompe Phase 1/2 Study - May 15 at 11:29 AM logoAmicus Therapeutics, Inc. (FOLD) Upgraded at Zacks Investment Research - May 12 at 10:06 PM logoQ1 2017 Earnings Estimate for Amicus Therapeutics, Inc. Issued By Leerink Swann (FOLD) - May 11 at 7:34 AM logoAmicus Therapeutics to Present at Two Upcoming Investor Conferences - May 10 at 9:32 AM logoEdited Transcript of FOLD earnings conference call or presentation 9-May-17 12:30pm GMT - May 10 at 9:32 AM logoAmicus Therapeutics' (FOLD) CEO John Crowley on Q1 2017 Results - Earnings Call Transcript - May 9 at 5:08 PM logoETFs with exposure to Amicus Therapeutics, Inc. : May 9, 2017 - May 9 at 5:08 PM logoAmicus Therapeutics, Inc. (FOLD) Posts Earnings Results, Misses Estimates By $0.02 EPS - May 9 at 11:24 AM logoAmicus Therapeutics, Inc. – Value Analysis (NASDAQ:FOLD) : May 8, 2017 - May 9 at 10:17 AM logoAmicus Therapeutics Announces First Quarter 2017 Financial Results and Corporate Updates - May 9 at 10:17 AM logoInvestor Network: Amicus Therapeutics, Inc. to Host Earnings Call - May 9 at 10:17 AM logoAmicus Therapeutics reports 1Q loss - May 9 at 8:59 AM logoAmicus Therapeutics, Inc. (FOLD) Scheduled to Post Earnings on Tuesday - May 7 at 7:08 AM logoAmicus Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : FOLD-US : May 5, 2017 - May 5 at 5:29 PM logo$4.1 Million in Sales Expected for Amicus Therapeutics, Inc. (FOLD) This Quarter - May 4 at 2:44 PM logoAmicus Therapeutics, Inc. (FOLD) Cut to "Sell" at Zacks Investment Research - May 3 at 1:10 AM logoAmicus Therapeutics Launches Galafold™ (Migalastat) for Treatment of Fabry Disease in France - May 2 at 7:41 PM logoAmicus Therapeutics to Announce First Quarter 2017 Financial Results on May 9, 2017 - May 2 at 7:41 PM logo-$0.37 EPS Expected for Amicus Therapeutics, Inc. (FOLD) This Quarter - May 2 at 8:34 AM logoAmicus Therapeutics (FOLD) Earns Daily News Sentiment Score of 0.01 - May 1 at 6:04 PM logoAmicus Therapeutics, Inc. (FOLD) Scheduled to Post Quarterly Earnings on Monday - April 29 at 1:22 AM logoAmicus Therapeutics, Inc. (FOLD) to Release Earnings on Monday - April 29 at 1:02 AM logoAmicus Therapeutics, Inc. (FOLD) Set to Announce Earnings on Monday - April 29 at 1:01 AM logoAmicus Therapeutics (FOLD) Earns Daily News Sentiment Score of 0.37 - April 28 at 2:06 PM logoAmicus Therapeutics, Inc. (FOLD) Receives Average Recommendation of "Buy" from Analysts - April 28 at 10:30 AM logoAmicus Therapeutics (FOLD) Earning Favorable News Coverage, Study Finds - April 24 at 4:10 PM logoAmicus Therapeutics: ~$7 Biotech Stock Still Has Upside - Seeking Alpha - April 22 at 4:56 PM logoAmicus Therapeutics (FOLD) Receiving Favorable News Coverage, Report Shows - April 20 at 4:22 PM logoAmicus Therapeutics (FOLD) Earns Media Impact Score of 0.11 - April 17 at 11:27 PM logoAmicus Therapeutics, Inc. (FOLD) Short Interest Down 1.8% in March - April 16 at 10:50 AM logoAmicus Therapeutics (FOLD) Earning Positive News Coverage, Study Finds - April 13 at 7:00 PM logoZacks: Brokerages Expect Amicus Therapeutics, Inc. (FOLD) Will Post Earnings of -$0.37 Per Share - April 11 at 12:20 AM logoAmicus Therapeutics Honors Fabry Disease Awareness Month and International Pompe Day - April 7 at 9:51 AM logoAmicus Therapeutics' (FOLD) "Outperform" Rating Reiterated at Leerink Swann - April 5 at 1:16 PM logoAmicus Therapeutics Completes Enrollment in ESSENCE Phase 3 Epidermolysis Bullosa Clinical Study - April 3 at 5:29 PM logoAmicus Therapeutics, Inc. (FOLD) Given Average Rating of "Buy" by Analysts - April 3 at 12:20 PM logoAmicus Therapeutics (FOLD) Finalizes Enrollment in ESSENCE Phase 3 Epidermolysis Bullosa Clinical Study - - April 3 at 9:39 AM



Amicus Therapeutics (FOLD) Chart for Saturday, May, 27, 2017

This page was last updated on 5/27/2017 by Staff